Research programme: cancer therapeutics - miRecule
Latest Information Update: 15 Oct 2024
At a glance
- Originator miRecule
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; RNA
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 25 Sep 2024 miRecule has patent protection for RNA chemistry to develop RNA therapeutics prior to September 2024 (miRecule website; September 2024)
- 25 Sep 2024 Early research in Cancer in USA (Parenteral) prior to September 2024 (miRecule pipeline; September 2024)